| Patient | Christopher Reeve |
|---|---|
| Date of birth | 1975-09-25 |
| Identifiers | MRN HR-ML024-SYN; SSN (made up) 000-24-7765 |
| Document date | 2026-04-13 |
| Author | Teresa Galloway, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
The patient attends this visit for establishing primary care for chronic C2 tetraplegia on a ventilator, some weeks after a diaphragm pacing system was implanted: autonomic dysreflexia plan, skin, bladder, bowel, respiratory care, bone and cardiometabolic health, mood, and care team needs. [S]
White cells: 7.2 10*3/uL; Hemoglobin: 13.1 g/dL (low); Sodium: 138 mmol/L; Potassium: 4.2 mmol/L; Creatinine: 0.48 mg/dL (low); Cystatin C: 0.92 mg/L; eGFR (cystatin C): 90 mL/min/1.73 m²; Albumin: 3.8 g/dL; Calcium: 9 mg/dL; 25-hydroxyvitamin D: 22 ng/mL (low); Parathyroid hormone (intact): 52 pg/mL; Hemoglobin A1c: 5.5%; Total cholesterol: 172 mg/dL; LDL cholesterol: 104 mg/dL; HDL cholesterol: 34 mg/dL (low); Triglycerides: 170 mg/dL (high); PHQ-9: 3; Braden scale: 11; Pain score (0 to 10): 3. [S]
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-13 | Body height | 193 | cm | S |
| 2026-04-13 | Body weight | 82 | kg | S |
| 2026-04-13 | Body mass index (BMI) [Ratio] | 22 | kg/m2 | S |
| 2026-04-13 | Systolic blood pressure | 104 | mm[Hg] | S |
| 2026-04-13 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 2026-04-13 | Heart rate | 62 | /min | S |
| 2026-04-13 | Respiratory rate | 12 | /min | S |
| 2026-04-13 | Body temperature | 36.3 | Cel | S |
| 2026-04-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-13 | Leukocytes [#/volume] in Blood by Automated count | 7.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-04-13 | Hemoglobin [Mass/volume] in Blood | 13.1 | g/dL | 13.2-16.6 g/dL | Low | S |
| 2026-04-13 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-13 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-13 | Creatinine [Mass/volume] in Serum or Plasma | 0.48 | mg/dL | 0.74-1.35 mg/dL | Low | S |
| 2026-04-13 | Cystatin C [Mass/volume] in Serum or Plasma | 0.92 | mg/L | 0.53-0.95 mg/L | Normal | S |
| 2026-04-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Cystatin C-based formula/1.73 sq M | 90 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-04-13 | Albumin [Mass/volume] in Serum or Plasma | 3.8 | g/dL | 3.5-5.2 g/dL | Normal | S |
| 2026-04-13 | Calcium [Mass/volume] in Serum or Plasma | 9 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-04-13 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 22 | ng/mL | 30-100 ng/mL | Low | S |
| 2026-04-13 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 52 | pg/mL | 15-65 pg/mL | Normal | S |
| 2026-04-13 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes | Normal | S |
| 2026-04-13 | Cholesterol [Mass/volume] in Serum or Plasma | 172 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-04-13 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 104 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-04-13 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 34 | mg/dL | >=40 mg/dL | Low | S |
| 2026-04-13 | Triglyceride [Mass/volume] in Serum or Plasma | 170 | mg/dL | <=149 mg/dL | High | S |
| 2026-04-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-04-13 | Braden scale total score | 11 | {score} | S | ||
| 2026-04-13 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 3 | {score} | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sennosides 8.6 mg oral tablet, two tablets at bedtime | Two tablets at bedtime | Oral route | 2026-04-13 | active | S |
| Nitroglycerin 2% ointment, one inch to the skin of the chest only if systolic blood pressure stays at 150 mmHg or higher after the first steps of the autonomic dysreflexia plan; wipe off when pressure falls | As needed for autonomic dysreflexia, under the written plan | Topical route | 2026-04-13 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets up to three times a day as needed for neck and shoulder aching | Two tablets up to three times a day as needed | Oral route | 2026-04-13 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic incomplete C2 tetraplegia (ASIA grade C) from a traumatic spinal cord injury in a riding fall eight years ago, with partial late recovery of sensation and movement; uses a power wheelchair and has 24-hour nursing support; at risk of autonomic dysreflexia; synthetic modern episode linked to his documented injury and his physicians' published report | active | confirmed | G82.52 | S — Synthetic modern coding of the documented injury and the published ASIA grade. |
| Chronic ventilatory failure from the high cervical injury: dependent on a ventilator through a tracheostomy, with a diaphragm pacing system implanted some weeks ago and a conditioning program to lengthen time on the pacer; synthetic modern episode linked to his documented ventilator use and pacing | active | confirmed | Z99.11 | S — Synthetic modern coding of the documented ventilator dependence. |
| Neurogenic bladder after spinal cord injury, managed with an indwelling catheter | active | confirmed | N31.9 | S — Synthetic; expected with this level of injury. No public source describes his bladder care. |
| Neurogenic bowel after spinal cord injury, managed with a daily morning bowel program | active | confirmed | K59.2 | S — Synthetic; expected with this level of injury. No public source describes his bowel care. |